

Lifepearl loaded with doxorubicin in a patient with HCC pre-transplant

Physician: Nuno Vasco Costa, MD

Location: Hepato-Biliary-Pancreatic and Transplantation Centre, Curry Cabral Hospital Lisboa, Portugal



CLINICAL CASE

55 years old male with alcoholic/hepatitis C virus related cirrhosis (abstinent in the last 10 years) and elevated serum liver enzymes (ALT, AST, ALP, GGT) with a Child-Pugh score of 6 points (A).

He developed two hepatocellular carcinoma (HCC) on the right liver lobe - VII (28 mm) and VIII (23 mm) segments - under the Milan criteria. Tumor board decision was to perform DEB-TACE as a bridging procedure until liver transplantation.

PROCEDURE

After local anesthesia of the skin and subcutaneous tissue, a 5F Simmons 2 catheter was placed through a 5F introducer in the coeliac trunk. DSA confirmed both lesions arising from the right hepatic artery.

Superselective embolization of the feeding arteries was performed by means of a microcatheter Progreat 2.7 F.



Two vials of LifePearl (200 µm), charged with 75 mg of doxorubicin each, were administered (one vial per lesion) until near stasis (stasis of contrast during 5 heartbeats).

FOLLOW UP/ CONCLUSION


The patient underwent CT scan at 1 and 6 months after the procedure. Complete response was achieved with total tumor necrosis and volumetric shrinkage of both liver lesions. No new lesions were detected during follow-up and the patient was successfully transplanted 8 months after DEB-TACE.

PRODUCTS USED

LifePearl 4 mL of microspheres + 150 mg doxorubicin (1 session)
5 F Simmons 2 catheter, 2.7 F progreat microcatheter and 0.021 GLIDEWIRE[®] GT Guidewire.



CT Images of Pre-TACE



Follow up CT Images

LifePearl[™] Microspheres are indicated for embolization of blood vessels supplying primary-hypervascular tumors or metastases in the liver.

Note: LifePearl[™] Microspheres can be loaded with chemotherapeutic drugs. When used for drug loading, drug loading should be done under a physician's direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. MICROVENTION is a registered trademark of MicroVention, Inc. LifePearl is a trademark of Terumo, Inc.

<https://www.terumo-europe.com/en-emea/Treat-liver-cancer-with-Terumo-2018>

byagency